Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Vosoritide (Voxzogo) Peptide
C-type natriuretic peptide analog for achondroplasia.
What is Vosoritide (Voxzogo)?
Vosoritide (Voxzogo) is a cnp analog · skeletal growth peptide studied for achondroplasia in children ≥5 years (now ≥4 months). Below is an educational overview of Vosoritide (Voxzogo) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Voxzogo
Achondroplasia in children with open growth plates (FDA-approved for ages 4 months and up).
A daily under-the-skin injection that counteracts the genetic signal limiting bone growth in achondroplasia.
- •Injection-site reactions
- •Vomiting
- •Decreased blood pressure (often briefly)
- •Joint pain
- •Fatigue
- •Symptomatic low blood pressure
- •Possible effect on blood pressure if dehydrated or fasting
- •Closed growth plates
- •Significant cardiovascular or cerebrovascular disease
- •Severe dehydration
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Vosoritide (Voxzogo) Mechanism of Action
Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.
Vosoritide (Voxzogo) Research Areas & Benefits
Vosoritide (Voxzogo) Dosage & Common Research Protocols
Weight-based daily subcutaneous injection.
Protocols summarized for educational reference from published research. Not dosing guidance.
Vosoritide (Voxzogo) Studies & Cited Research
Vosoritide Phase 3 trial
Increased annualized growth velocity vs placebo in children with achondroplasia.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Vosoritide (Voxzogo) Side Effects & Safety Considerations
- •FDA-approved.
- •Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.